DANA-FARBER CANCER INSTITUTE and Astellas Pharma Inc. announced a three-year collaboration to research and develop small molecule inhibitors of oncogenic K-Ras for the treatment of cancer.
NYU LANGONE Medical Center and Lutheran Medical Center will create a clinically integrated health care provider network for the New York metropolitan area.
MERCK KGAA and Pfizer Inc. will co-develop and co-commercialize MSB0010718C, an investigational anti-PD-L1 antibody currently in development by Merck KGaA as a potential treatment for multiple tumor types.\
SUSAN MAYNE was appointed director of the FDA Center for Food Safety and Applied Nutrition.
BERT VOGELSTEIN was awarded the 2014 Warren Triennial Prize by Massachusetts General Hospital.
THE BARBARA ANN KARMANOS CANCER INSTITUTE was honored by the Michigan Cancer Consortium with the 2014 Spirit of Collaboration Award for its Jewish Women's Health Project; and also received an Honorable Mention for its Harley Men's Health Event.
ST. JUDE CHILDREN'S RESEARCH HOSPITAL dedicated and opened The Marlo Thomas Center for Global Education & Collaboration on the St. Jude campus in Memphis, Tenn., Nov. 20. The center will focus on childhood cancer.
D. GARY GILLILAND was named president and director of the Fred Hutchinson Cancer Research Center, effective Jan. 2, 2015.
MARK GILBERT was named chief of the Neuro-Oncology Branch at the NIH, within the Center for Cancer Research of NCI.
ASTRAZENECA, Pharmacyclics Inc. and Janssen Research & Development LLC entered into a clinical trial collaboration to evaluate the efficacy and safety of AstraZeneca's investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, in combination with Imbruvica (ibrutinib).